Superluminal Medicines

Superluminal Medicines

Superluminal Medicines is a biotechnology company using AI and machine learning for drug discovery. They focus on rare genetic forms of obesity and hypothalamic obesity. This Series B funding will advance their lead program for rare genetic forms of obesity toward a first clinical trial.

Total raised
Undisclosed
tracked to date
Latest round
Series B
Sep 3, 2026
Known investors
8
led by BVF Partners, L.P.

Is this your company?

Claim this profile to get matched with investors who fund Health startups in United States.

Claim this profile →

🏆 Featured in Datapile’s Q3 2026 USA Funding Report

Read the Q3 2026 USA report →
Add this badge to your site
<a href="https://datapile.co/reports/q3-2026-usa-startup-funding" target="_blank" rel="noopener" style="display:inline-flex;align-items:center;gap:8px;padding:9px 16px;border-radius:9999px;background:#0B1224;color:#ffffff;font:600 13px/1.2 -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Arial,sans-serif;text-decoration:none;border:1px solid #7C5CFF"><span style="display:inline-block;width:11px;height:11px;border-radius:3px;background:#7C5CFF"></span>Featured in Datapile&rsquo;s Q3 2026 USA Funding Report</a>

Funding history

  1. 1
    $60 million Series BSeries BSep 3, 2026

    Led by BVF Partners, L.P.

    Announcement ↗

Founder

Cony D’Cruz
Cony D’Cruz
Chief Executive Officer

Investors in Superluminal Medicines

Backers from this company's tracked funding rounds.

  • BBVF Partners, L.P.Lead investorVC firm
  • DDeep Track CapitalVC firm
  • PPerceptive AdvisorsVC firm
  • RRA Capital ManagementVC firm
  • IInsight PartnersVC firm
  • NNVIDIAVC firm
  • CCatalio Capital ManagementVC firm
  • EEli Lilly and CompanyVC firm

Superluminal Medicines in the news

Coverage of this company's funding, tracked by Datapile.

More Health companies

Recently funded startups in the same category.

Related on Datapile